Sumitomo Pharma Co., Ltd.
FY2026 Q2 Earnings Presentation Materials
In the FY2026 Q2 overview, revenue was revised upward for the full-year forecast. Core operating profit increased, driven by expanded contributions from key products such as Orgovix in the US market. The full-year forecast was partially revised and the year-end dividend is planned at 15 yen per share.
Key Figures
- Revenue: 2,665 hundred million yen (Year-over-Year +17.3%)
- Cost of Sales: 1,235 hundred million yen (Year-over-Year +37.7%)
- Operating Income: 962 hundred million yen (Year-over-Year -56.0%)
AI要約
Earnings Overview
FY2026 Q2 results were supported by strength in certain regions, including contributions from the US market, with revenue increasing to 266.5 billion yen year-over-year. Although gross profit expanded despite rising costs, increases in selling, general and administrative expenses and R&D expenses pressured profits. While core operating profit has room for improvement, the company raised its full-year outlook reflecting revisions made at the beginning of the fiscal year.
Outlook and Dividends
The full-year forecast was revised taking into account foreign exchange impact, and a year-end dividend of 15 yen per share is planned. Milestone achievements in the US market centered on Orgovix are expected to continue to support revenue uplift. R&D expenses are expected to increase mainly in oncology and neuropsychiatric areas, but overall the company expects to remain on a growth trajectory.
Revenue Trend
Operating Income Trend
Segment Revenue Composition
Gross Margin Trend
Forecast vs Actual Comparison
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
